Media Articles Related to Edluar (Zolpidem)
Zolpidem Paradox: Why Sleep Med Wakes Brain-Injured Patients
Source: Medscape Anesthesiology Headlines [2013.11.27]
Researchers may have solved the mystery of why the sleep agent zolpidem has a paradoxical awakening effect in some patients who are minimally conscious following a severe brain injury.
Medscape Medical News
Insomnia linked to higher risk of death
Source: Cardiovascular / Cardiology News From Medical News Today [2013.11.22]
A new study of men by researchers from Brigham and Women's Hospital in Boston, MA, has found that some insomnia symptoms are linked to a higher risk of death.
Insomnia Cure Boosts Success of Depression Treatment, Study Finds
Source: MedicineNet Depression Specialty [2013.11.20]
Title: Insomnia Cure Boosts Success of Depression Treatment, Study Finds
Category: Health News
Created: 11/19/2013 4:36:00 PM
Last Editorial Review: 11/20/2013 12:00:00 AM
Prescription Sleep Aids a Common Choice for American Insomnia
Source: MedicineNet temazepam Specialty [2013.08.29]
Title: Prescription Sleep Aids a Common Choice for American Insomnia
Category: Health News
Created: 8/29/2013 9:35:00 AM
Last Editorial Review: 8/29/2013 12:00:00 AM
10 Tips to Avoid Insomnia and Get a Good Night's Sleep
Source: MedicineNet alprazolam Specialty [2012.08.07]
Title: 10 Tips to Avoid Insomnia and Get a Good Night's Sleep
Category: Doctor's Views
Created: 6/14/2005 12:00:00 AM
Last Editorial Review: 8/7/2012 12:00:00 AM
Published Studies Related to Edluar (Zolpidem)
Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. [2011.07]
CONCLUSIONS: Zolpidem extended-release administered concomitantly with escitalopram for up to 24 weeks was well tolerated and improved insomnia and some sleep-related next-day symptoms and next-day functioning in patients with MDD but did not significantly augment the antidepressant response of escitalopram. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00296179. (c) Copyright 2011 Physicians Postgraduate Press, Inc.
The use of a non-benzodiazepine hypnotic sleep-aid (Zolpidem) in patients undergoing ACL reconstruction: a randomized controlled clinical trial. [2011.05]
PURPOSE: Previous studies have addressed post-operative pain management after ACL reconstruction by examining the use of intra-articular analgesia and/or modification of anesthesia techniques. To our knowledge, however, no previous studies have evaluated the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction. The purpose of this prospective, blinded, randomized, controlled clinical study was to evaluate the effect of zolpidem on post-operative narcotic requirements, pain, and fatigue in patients undergoing outpatient arthroscopic ACL reconstruction... CONCLUSION: Adding zolpidem to the post-operative medication regimen after arthroscopic ACL reconstruction helps to lower the amount of narcotic pain medication required for adequate analgesia. LEVEL OF EVIDENCE: Randomized controlled clinical trial, Level I.
Zolpidem and zopiclone impair similarly monotonous driving performance after a single nighttime intake in aged subjects. [2011.04]
RATIONALE: Although hypnotics are primarily used by older people, the residual effects the morning after a single nighttime intake of the two most commonly prescribed hypnotics, zolpidem (Zp) and zopiclone (Zc), on older middle-aged drivers have not been evaluated and compared... CONCLUSIONS: This is the first study revealing residual effects of Zp on driving performance in ageing drivers which are similar to that of Zc. Studying the effects of medication in different age ranges appears useful to complete the studies on behavioural-pharmacological effects of medication. To reduce the incidence of driving accidents due to prescription drugs, patients should be warned at the time of treatment initiation that they should avoid driving.
Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study. [2011.02.01]
STUDY OBJECTIVES: To assess hypnotic self-administration and likelihood of dose escalation over 12 months of nightly use of zolpidem versus placebo in primary insomniacs... CONCLUSIONS: Zolpidem was preferred to placebo, but its self-administration did not increase with 12 months of use. Chronic hypnotic use by primary insomniacs does not lead to dose escalation.
A double-blind, randomized, comparative study to evaluate the efficacy and safety of zaleplon versus zolpidem in shortening sleep latency in primary insomnia. [2011.01]
BACKGROUND: Benzodiazepines cause a high proportion of adverse effects while non-benzodiazepine compounds have demonstrated high efficacy and less adverse effects in patients with insomnia. The objective of this study was to compare the effectiveness and safety of non-BZ zaleplon and zolpidem in primary insomnia... CONCLUSION: There was no significant difference between zaleplon and zolpidem in the efficacy of reducing sleep latency or adverse effects. A large pharmacovigilance study is needed before concluding that either zolpidem or zaleplon is free from next-day residual effects.
Clinical Trials Related to Edluar (Zolpidem)
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients [Recruiting]
The purpose of this study is to investigate the efficacy and safety of zolpidem MR (modified
release) compared to zolpidem IR (immediate release) in patients with primary insomnia.
Zolpidem CR and Hospitalized Patients With Dementia [Recruiting]
The purpose of this research study is to compare the effectiveness of Zolpidem CR to that of
placebo in improving sleep efficiency in people with dementia admitted to the hospital
because of their symptoms. You can participate in this study if you have dementia of the
Alzheimer's type or vascular dementia. This study involves placebo; a placebo is a tablet
that looks exactly like Zolpidem CR, the study drug, but contains no active study drug. We
will use placebos to see if the study results are due to the study drug or due to other
reasons. Zolpidem CR is also called Ambien CR and is widely available by prescription.
Zolpidem CR is approved by the U. S. Food and Drug Administration (FDA) for the short-term
treatment of insomnia (trouble falling or staying asleep).
Use of Zolpidem in Parkinson's Disease [Not yet recruiting]
Levodopa treatment is associated with long-term complications. Dopamine deficiency is
associated with abnormal activity in certain parts of the brain. Zolpidem may change this
abnormal activity and, by doing so, may work in a different way than levodopa to help
The working hypothesis for this aim is that ZLP is superior to placebo in acutely improving
motor symptoms of PD. The investigators will conduct a randomized,controlled, double-blind,
cross-over study in 40 patients with PD. Each patient will receive placebo, levodopa and 2
doses of ZLP in a randomized order on 4 different occasions, about one week apart.
Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T [Recruiting]
The primary goal of this double-blind, placebo-controlled, within-subjects functional
neuroimaging study is to examine the extent to which the hypnotic zolpidem decreases brain
activity in regions of the brain known to process emotional information. Although zolpidem
is an effective sleep-aid, its ability to engender anti-anxiety effects is equivocal, yet
promising. Zolpidem's activity during tasks that engage anxiety-related processes in the
brain will be compared to that of the known anxiolytic drug alprazolam, a positive
comparator caffeine, and placebo. A secondary goal of this study is to compare the
subjective drug effects, or how individuals feel, following the interventions. These
measures will be used to determine the existence of brain-behavior relationships, thus
demonstrating that imaging is an important tool for informing us about how drugs produce
their effects in the brain.
A Study to Evaluate Efficacy and Safety of Zolpidem Modified Release Formulation in Insomnia Patients [Recruiting]
The purpose of the study is to investigate the efficacy and safety of zolpidem modified
release (MR) tablet using estazolam (Eurodin) as a comparative drug in patients with primary